Anne Wojcicki is not profitable to get 23andme

23andme besieged genetic tests Advertise Friday She has reached an agreement to sell itself to a non -profit institution led by the co -founder of the company and former CEO Ann Wajiki.

After a huge electronic attack in 2023 and settling a related lawsuit, 23andme It was submitted to bankruptcy In March, with the resignation of WoJCICKKI to become an independent bidder for the company. But the drug company Regeneron was The company has been announced With $ 256 million.

According to the Wall Street JournalThe TTAM Non -Performing Research Institute in WoJCICKI reopened the bidding process by making an unwanted offer earlier this month, and Regeneron refused to overcome the TTAM of $ 305 million.

In this announcement, TTAM (an abbreviation that corresponds to the first messages of twenty -three and me) that customers will be notified of at least two commercial deals before the deal is closed, and that non -profit organizations will continue to adhere to the 23ndme privacy policies that allow customers to communicate with customers Delete their data And the research subscription. It also mentioned that it would create a consultative council for consumer privacy within 90 days of closure.

“I feel overwhelmed because the TTAM Research Institute will be able to continue the 23DME mission to help people reach, understand and benefit from the human genome,” WoJCICKKI wrote on LinkedIn. “We believe that it is very important that individuals be able to choose and transparently regarding their genetic data and have the opportunity to continue to identify their grandparents and health risks as they wish.”

The acquisition process is still approved by the bankruptcy court, and it faces additional legal obstacles – a group of 28 state lawyers led by Letitia James in New York litigate This week, he objected to the sale of the company’s assets.

James said: “23ndme cannot public auction millions of personal genetic information for people without their consent.”

The Orthodox Secretary for Privacy appointed by the court also said that it is not clear that 23ndme privacy policies allow the sale of its genetic data, according to WSJ.

It is also not clear that 23andme can regain consumer confidence if the deal continues. Joseph Silsafag, the company’s temporary CEO, told the House of Representatives a committee 15 % of customers have requested to delete their data Since the company has applied for bankruptcy.